Trust the Evidence

Share this post

The Story of Influenza Antivirals: Part 2

trusttheevidence.substack.com

The Story of Influenza Antivirals: Part 2

The Emergence of Tamiflu

Tom Jefferson
and
Carl Heneghan
Mar 21, 2023
∙ Paid
56
Share this post

The Story of Influenza Antivirals: Part 2

trusttheevidence.substack.com
3
Share

Share

The first Neuraminidase inhibitor (NI) to be licensed by its manufacturer Glaxo Wellcome and SmithKline Beecham (who went on to form GSK) in 1999 was zanamivir (Relenza), an inhaled diskhaler powder. This was closely followed by oseltamivir (patented by Gilead Science and marketed by Roche) in late 1999: a capsule for oral consumption, usually three tim…

Keep reading with a 7-day free trial

Subscribe to

Trust the Evidence
to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2023 Carl Heneghan
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing